- Report
- July 2026
- 160 Pages
Global
From €3770EUR$4,150USD£3,215GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,478GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,478GBP
- Report
- May 2026
- 140 Pages
Global
From €2724EUR$2,999USD£2,323GBP
€3633EUR$3,999USD£3,098GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1135EUR$1,250USD£968GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3406EUR$3,750USD£2,905GBP
- Report
- May 2024
- 129 Pages
Global
From €2724EUR$2,999USD£2,323GBP
€3633EUR$3,999USD£3,098GBP
Ambisome is a brand of liposomal amphotericin B, an antifungal drug used to treat a variety of fungal infections. It is used to treat serious fungal infections in patients with weakened immune systems, such as those with HIV/AIDS, cancer, or organ transplants. Ambisome is a polyene antifungal drug, meaning it works by binding to the cell membrane of the fungus and disrupting its structure. It is generally used as a last resort when other antifungal drugs have failed.
Ambisome is part of the larger Infectious Diseases Drugs market, which includes a variety of drugs used to treat bacterial, viral, and fungal infections. These drugs are used to treat a wide range of infections, from common colds to life-threatening illnesses.
Some companies in the Infectious Diseases Drugs market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, and Novartis. Show Less Read more